"MIRACLE" FAT-MELTING DRUG OZEMPIC HAS been linked in a study to a series of rare but potentially fatal psychiatric episodes, scientists have warned.
The injectable prescription drug was developed to manage blood sugar levels in patients with Type 2 diabetes, but it has gained popularity and gone viral on social media due to one sought-after side effect: weight loss.
Ozempic is based on a naturally occurring human hormone called glucagon-like peptide 1, which plays an important role in regulating appetite and blood sugar levels. Its active ingredient is a molecule called semaglutide, which mimics the structure of this GLP-1 hormone and activates its receptors.
In doing so, semaglutide induces feelings of fullness while delaying the emptying of our stomach, making us less hungry and therefore less likely to overeat.
Semaglutide is also used in Ozempic's sister drug, Wegovy, which has been approved by the FDA for chronic weight management. Between the start of 2020 and the end of 2022, prescriptions of GLP-1 mimic medications like semaglutide increased by 300 percent across the U.S., according to health care analytics firm Trilliant Health.
The drug has since been endorsed by celebrities and influencers, with #ozempic reaching over 1.4 billion views on TikTok. However, when used as a weight-loss drug, semaglutide has been shown to have some uncomfortable side effects.
Most studies into these have focused on gut problems, but a new study, published in the International Journal of Clinical Pharmacy, has highlighted a concerning association between semaglutide and adverse psychiatric events, including depression, anxiety and suicidal thoughts. Pharmaceutical manufacturer Novo Nordisk, which produces Ozempic and Wegovy, cited the FDA saying that no evidence was found regarding suicidal thoughts or actions caused by these medicines.
This story is from the March 22, 2024 edition of Newsweek Europe.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 22, 2024 edition of Newsweek Europe.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Ray Romano
THE MAJOR THING ABOUT NETFLIX'S NO GOOD DEED THAT APPEALED TO Ray Romano was that it was unlike anything he'd done before.
Has J.K. Rowling Won the Culture War?
After years of backlash over trans issues, the Harry Potter author has received major business backing
'This Murder Is a Symbol of the Times'
Conservatives and liberals agree on the state of the health care industry following the killing of Brian Thompson
The Defense Industry's Fight With ESG
EUROPEAN DEFENSE COMPANIES, ESPECIALLY smaller businesses, are being blocked from investment they sorely need by sustainability rules, a senior NATO official and several industry figures have said.
Nothin' Lasts Forever
Taylor Swift's Eras Tour' ends its record-breaking run..
SPY IN THE SKY
CHINA FACES ACCUSATIONS of ESPIONAGE and WEAPONIZING OUTER SPACE as it BUILDS a NEW OBSERVATORY in CHILE critics say WILL BE USED for MILITARY PURPOSES
Margo Martindale
\"WHO KNEW THAT A BARREL OF MAPLE SYRUP IS WORTH MORE THAN A barrel of oil?\"
Malala Yousafzai
\"AFGHANISTAN IS THE ONLY COUNTRY IN THE world where girls are banned from access to education and women are limited from work.\"
In the Eyes of the Law
Jude Law is unrecognizable as an FBI agent on the trail of aneo-Naziterrorist group in real-crime drama The Order
AMERICA'S Most Responsible Companies 2025
IN THE FACE OF ISSUES LIKE CLIMATE CHANGE and wage inequality, consumers care about the impact of the businesses they interact with and companies are responding.
